Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo

International Journal of Cancer

Volumn 128, Issue 7, 2011, Pages 1703-1711

  Gleissman, Helena ^a   Segerström, Lova ^a   Hamberg, Mats ^a   Ponthan, Frida ^b   Lindskog, Magnus ^a,c   Johnsen, John Inge ^a   Kogner, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

docosahexaenoic acid; neuroblastoma; omega 3 fatty acids; pediatric cancer; preclinical in vivo models

Indexed keywords

DOCOSAHEXAENOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; GAS LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; NEUROBLASTOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, GAS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FATTY ACIDS; FATTY ACIDS, OMEGA-3; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KINETICS; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RATS; RATS, NUDE;

EID: 79551501515     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25473     Document Type: Article

References (62)

1. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
2. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK,. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol 2009; 27: 1290-6.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL,. Neuroblastoma. Lancet 2007; 369: 2106-20.
4. Berquin IM, Edwards IJ, Chen YQ,. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008; 269: 363-77.
5. Moyad MA,. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II. Urol Oncol 2005; 23: 36-48.
6. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A,. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004; 79: 935-45.
7. Stillwell W, Wassall SR,. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126: 1-27.
8. Belkind-Gerson J, Carreon-Rodriguez A, Contreras-Ochoa CO, Estrada-Mondaca S, Parra-Cabrera MS,. Fatty acids and neurodevelopment. J Pediatr Gastroenterol Nutr 2008; 47 (Suppl 1): S7-9.
9. Reynolds LM, Dalton CF, Reynolds GP,. Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett 2001; 309: 193-6.
10. Martin DD, Robbins ME, Spector AA, Wen BC, Hussey DH,. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids 1996; 31: 1283-8.
11. Kokoglu E, Tuter Y, Yazici Z, Sandikci KS, Sonmez H, Ulakoglu EZ, Ozyurt E,. Profiles of the fatty acids in the plasma membrane of human brain tumors. Cancer Biochem Biophys 1998; 16: 301-12.
12. Schmitz G, Ecker J,. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008; 47: 147-55.
13. Serhan CN, Chiang N, van Dyke TE,. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-61.
14. Hata AN, Breyer RM,. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103: 147-66.
15. Fulton A, Miller F, Weise A, Wei WZ,. Prospects of controlling breast cancer metastasis by immune intervention. Breast Dis 2006; 26: 115-27.
16. Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist CO, Holm S, Gustavsson B, Kagedal B, Kogner P, Johnsen JI,. Tumor-growth- promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 2008; 10: 661-74.
17. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, Sveinbjornsson B, Kogner P,. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004; 64: 7210-5.
18. Ponthan F, Wickstrom M, Gleissman H, Fuskevag OM, Segerstrom L, Sveinbjornsson B, Redfern CP, Eksborg S, Kogner P, Johnsen JI,. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 2007; 13: 1036-44.
19. Sveinbjornsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, Ponthan F, Orrego A, Haeggstrom JZ, Johnsen JI, Kogner P,. Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J 2008; 22: 3525-36.
20. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI,. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 2006; 118: 2584-93.
21. Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P,. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J 2010; 24: 906-15.
22. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, et al. The Pediatric Preclinical Testing Program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-40.
23. Lepage G, Roy CC,. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986; 27: 114-20.
24. Rusca A, Di Stefano AF, Doig MV, Scarsi C, Perucca E,. Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 503-10.
25. Arterburn LM, Hall EB, Oken H,. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006; 83: 1467S-76S.
26. Childs CE, Romeu-Nadal M, Burdge GC, Calder PC,. Gender differences in the n-3 fatty acid content of tissues. Proc Nutr Soc 2008; 67: 19-27.
27. Pelicano H, Carney D, Huang P,. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7: 97-110.
28. Akihisa T, Tokuda H, Ogata M, Ukiya M, Iizuka M, Suzuki T, Metori K, Shimizu N, Nishino H,. Cancer chemopreventive effects of polyunsaturated fatty acids. Cancer Lett 2004; 205: 9-13.
29. Manna S, Chakraborty T, Ghosh B, Chatterjee M, Panda A, Srivastava S, Rana A,. Dietary fish oil associated with increased apoptosis and modulated expression of Bax and Bcl-2 during 7,12-dimethylbenz(alpha)anthracene-induced mammary carcinogenesis in rats. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 5-14.
30. Yuri T, Danbara N, Tsujita-Kyutoku M, Fukunaga K, Takada H, Inoue Y, Hada T, Tsubura A,. Dietary docosahexaenoic acid suppresses N-methyl-N-nitrosourea- induced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid. Nutr Cancer 2003; 45: 211-7.
31. Noguchi M, Minami M, Yagasaki R, Kinoshita K, Earashi M, Kitagawa H, Taniya T, Miyazaki I,. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br J Cancer 1997; 75: 348-53.
32. Toriyama-Baba H, Iigo M, Asamoto M, Iwahori Y, Park CB, Han BS, Takasuka N, Kakizoe T, Ishikawa C, Yazawa K, Araki E, Tsuda H,. Organotropic chemopreventive effects of n-3 unsaturated fatty acids in a rat multi-organ carcinogenesis model. Jpn J Cancer Res 2001; 92: 1175-83.
33. Takahashi M, Minamoto T, Yamashita N, Yazawa K, Sugimura T, Esumi H,. Reduction in formation and growth of 1,2-dimethylhydrazine-induced aberrant crypt foci in rat colon by docosahexaenoic acid. Cancer Res 1993; 53: 2786-9.
34. Iigo M, Nakagawa T, Ishikawa C, Iwahori Y, Asamoto M, Yazawa K, Araki E, Tsuda H,. Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br J Cancer 1997; 75: 650-5.
35. Ramos EJ, Middleton FA, Laviano A, Sato T, Romanova I, Das UN, Chen C, Qi Y, Meguid MM,. Effects of omega-3 fatty acid supplementation on tumor-bearing rats. J Am Coll Surg 2004; 199: 716-23.
36. Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K,. Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia 2006; 8: 112-24.
37. Victory R, Saed GM, Diamond MP,. Antiadhesion effects of docosahexaenoic acid on normal human peritoneal and adhesion fibroblasts. Fertil Steril 2007; 88: 1657-62.
38. Yi L, Zhang QY, Mi MT,. [Role of Rho GTPase in inhibiting metastatic ability of human prostate cancer cell line PC-3 by omega-3 polyunsaturated fatty acid]. Ai Zheng 2007; 26: 1281-6.
39. Goua M, Mulgrew S, Frank J, Rees D, Sneddon AA, Wahle KW,. Regulation of adhesion molecule expression in human endothelial and smooth muscle cells by omega-3 fatty acids and conjugated linoleic acids: involvement of the transcription factor NF-kappaB? Prostaglandins Leukot Essent Fatty Acids 2008; 78: 33-43.
40. Schaefer MB, Wenzel A, Fischer T, Braun-Dullaeus RC, Renner F, Dietrich H, Schaefer CA, Seeger W, Mayer K,. Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: impact on adhesion and apoptosis. Atherosclerosis 2008; 197: 630-7.
41. Rose DP, Connolly JM,. Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol 1999; 15: 1011-5.
42. Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N, Ranelletti FO, Palozza P,. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 2005; 55: 12-20.
43. Danbara N, Yuri T, Tsujita-Kyutoku M, Sato M, Senzaki H, Takada H, Hada T, Miyazawa T, Okazaki K, Tsubura A,. Conjugated docosahexaenoic acid is a potent inducer of cell cycle arrest and apoptosis and inhibits growth of colo 201 human colon cancer cells. Nutr Cancer 2004; 50: 71-9.
44. Yamagami T, Porada CD, Pardini RS, Zanjani ED, Almeida-Porada G,. Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biol Ther 2009; 8: 331-7.
45. Jude S, Roger S, Martel E, Besson P, Richard S, Bougnoux P, Champeroux P, Le Guennec JY,. Dietary long-chain omega-3 fatty acids of marine origin: a comparison of their protective effects on coronary heart disease and breast cancers. Prog Biophys Mol Biol 2006; 90: 299-325.
46. Arita K, Kobuchi H, Utsumi T, Takehara Y, Akiyama J, Horton AA, Utsumi K,. Mechanism of apoptosis in HL-60 cells induced by n-3 and n-6 polyunsaturated fatty acids. Biochem Pharmacol 2001; 62: 821-8.
47. Gani OA, Sylte I,. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. J Mol Graph Model 2008; 27: 217-24.
48. Zapata-Gonzalez F, Rueda F, Petriz J, Domingo P, Villarroya F, Diaz-Delfin J, de Madariaga MA, Domingo JC,. Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids. J Leukoc Biol 2008; 84: 1172-82.
49. de Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, Perlmann T,. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000; 290: 2140-4.
50. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG,. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27: 1007-13.
51. Zand H, Rahimipour A, Salimi S, Shafiee SM,. Docosahexaenoic acid sensitizes Ramos cells to gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem 2008; 317: 113-20.
52. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O,. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 2009; 101: 1978-85.
53. Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV,. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer 2008; 60 (Suppl 1): 81-9.
54. Lanier AP, Holck P, Ehrsam Day G, Key C,. Childhood cancer among Alaska Natives. Pediatrics 2003; 112: e396.
55. Lucas M, Dewailly E, Muckle G, Ayotte P, Bruneau S, Gingras S, Rhainds M, Holub BJ,. Gestational age and birth weight in relation to n-3 fatty acids among Inuit (Canada). Lipids 2004; 39: 617-26.
56. Dewailly E, Blanchet C, Lemieux S, Sauve L, Gingras S, Ayotte P, Holub BJ,. n-3 Fatty acids and cardiovascular disease risk factors among the Inuit of Nunavik. Am J Clin Nutr 2001; 74: 464-73. (Pubitemid 32880256)
57. Simopoulos AP,. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002; 56: 365-79.
58. Fradet V, Cheng I, Casey G, Witte JS,. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009; 15: 2559-66.
59. Wolk A, Larsson SC, Johansson JE, Ekman P,. Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA 2006; 296: 1371-6.
60. Kim J, Lim SY, Shin A, Sung MK, Ro J, Kang HS, Lee KS, Kim SW, Lee ES,. Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study. BMC Cancer 2009; 9: 216.
61. Alessandri JM, Guesnet P, Vancassel S, Astorg P, Denis I, Langelier B, Aid S, Poumes-Ballihaut C, Champeil-Potokar G, Lavialle M,. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 2004; 44: 509-38.
62. Auestad N, Scott DT, Janowsky JS, Jacobsen C, Carroll RE, Montalto MB, Halter R, Qiu W, Jacobs JR, Connor WE, Connor SL, Taylor JA, et al. Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics 2003; 112: e177-83.